European Organization for Research and Treatment for Cancer Quality of Life Questionnaire

Abstract

The European Organization for Research and Treatment for Cancer Quality of Life Questionnaire (EORTC QLQ system) represents one of the most rigorously evaluated and internationally adopted measurement traditions in oncology and health-related quality of life (HRQoL) assessment. Developed by the EORTC Quality of Life Group (initiated under the leadership of Neil K. Aaronson and international collaborators in 1988 and formalized with the core module in 1993), the modular assessment architecture couples a generic, cancer-specific core questionnaire (EORTC QLQ-C30) with disease-specific, site-specific, or treatment-specific supplemental modules. Among the most widely validated and utilized disease modules is the 13-item lung cancer module (EORTC QLQ-LC13), engineered specifically to capture disease symptoms and therapeutic side effects characteristic of lung cancer and its modern multimodality treatments (such as radiotherapy, chemotherapy, and surgical resection).

The instrument incorporates a 13-item structure comprised of one multi-item composite scale (the dyspnoea scale, containing 3 items assessing resting, walking, and stair-climbing breathlessness) and ten single-item symptom and treatment toxicity indicators: coughing, haemoptysis (coughing up blood), sore mouth/tongue, dysphagia, peripheral neuropathy (tingling hands or feet), alopecia (hair loss), site-specific pain (chest pain, arm/shoulder pain, and pain in other parts), and analgesic use. All items utilize a standardized 4-point Likert-type response format ranging from 1 (“Not at all”) to 4 (“Very much”), which are linearly transformed onto an intuitive 0 to 100 metric where higher scores denote greater symptom severity and functional burden. Extensive international field evaluations demonstrate high internal consistency for the dyspnoea scale (Cronbach’s α ≥ .80 to .88), exceptional clinical criterion validity, strong responsiveness to changes in performance status (e.g., Eastern Cooperative Oncology Group [ECOG] and Karnofsky scores), and robust prognostic utility for overall survival in randomized clinical trials.

Keywords

EORTC QLQ-C30, EORTC QLQ-LC13, health-related quality of life, psychometrics, oncology patient-reported outcomes, lung cancer symptoms, dyspnoea, cancer clinical trials, symptom burden, measurement invariance

Authors

The development of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life assessment architecture was spearheaded by the international, multidisciplinary EORTC Quality of Life Group (EORTC QLG), formally established in 1986 under the auspices of the EORTC. The conceptualization, psychometric operationalization, and initial cross-cultural validation of the core cancer module were led by:

• Neil K. Aaronson, Ph.D. — Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute (Antoni van Leeuwenhoek), Amsterdam, The Netherlands. Dr. Aaronson served as the lead investigator and primary architect of the core measurement strategy.
• Suresh Ahmedzai, M.D. — Department of Palliative Medicine, Sheffield University, Sheffield, United Kingdom.
• Bengt Bergman, M.D., Ph.D. — Department of Pulmonary Medicine, Renströmska Hospital and Sahlgrenska University Hospital, University of Göteborg, Sweden (lead investigator for the lung cancer-specific module, QLQ-LC13).
• Mogens Groenvold, M.D., Ph.D. — Department of Public Health, University of Copenhagen, and Palliative Care Research Group, Bispebjerg Hospital, Copenhagen, Denmark.
• Dominique Curran, M.Sc. — EORTC Data Center, Brussels, Belgium.
• David Osoba, M.D. — Department of Medicine, British Columbia Cancer Agency and University of British Columbia, Vancouver, Canada.
• Marianne A. Sullivan, Ph.D. — Department of Pulmonary Medicine and Sahlgrenska University Hospital, University of Göteborg, Sweden.

Institutional oversight and scientific repository maintenance are hosted by the EORTC Quality of Life Department, Avenue E. Mounier 83/11, 1200 Brussels, Belgium.

Purpose

The primary clinical and psychometric purpose of the European Organization for Research and Treatment for Cancer Quality of Life Questionnaire system is to provide a standardized, cross-culturally validated, multidimensional system for measuring patient-reported outcomes (PROs) within clinical oncology trials, observational registries, and palliative clinical practice. Historically, clinical oncology research prioritized physician-reported outcomes, objective tumor response criteria (e.g., RECIST), progression-free survival (PFS), and overall survival (OS). However, biomedical endpoints routinely fail to capture the profound subjective burden imposed by malignancy and aggressive therapeutic regimens such as combination cytotoxic chemotherapy, high-dose thoracic radiotherapy, immunotherapy, and radical surgical intervention.

To resolve this gap, the EORTC modular approach was devised. Its foundational purpose is twofold: first, to deliver a universally applicable core instrument (the QLQ-C30) that quantifies broad functional domains (physical, role, emotional, cognitive, and social) and common cancer-related symptoms; and second, to deliver validated organ- and disease-specific supplementary modules—such as the lung cancer questionnaire module (QLQ-LC13)—that focus directly on the discrete, high-impact clinical manifestations of the specific malignancy and its targeted toxicities. The specific clinical and psychometric aims of this system include:

• Evaluating Treatment Tolerability and Toxicities: Differentiating the side-effect profiles of alternative therapeutic regimens (for instance, platinum-doublet chemotherapy versus targeted tyrosine kinase inhibitors or concurrent chemoradiotherapy) in terms of patient-experienced treatment toxicities, including peripheral neuropathy, alopecia, dysphagia, and radiation-induced mucositis.
• Tracking Longitudinal Disease Trajectories: Sensitively capturing symptom progression, palliation, or recurrence across repeated cycles of cancer therapy, thereby signaling clinical progression before gross radiological deterioration is confirmed.
• Assisting Shared Decision-Making: Offering patients and clinicians standardized, quantifiable information regarding expected symptom burdens and trajectory expectations, thereby supporting realistic goal-setting in advanced or palliative care contexts.
• Establishing Prognostic Biomarkers: Serving as independent baseline and longitudinal prognostic predictors. Numerous pooled clinical trial analyses demonstrate that baseline patient-reported symptoms (notably dyspnoea, pain, and appetite loss) frequently predict overall survival independently of classic clinical prognostic variables such as performance status, stage, and histology.

Psychological Construct

The psychological and clinical construct measured by this instrument is health-related quality of life (HRQoL) within the specialized context of thoracic oncology. Under the EORTC conceptual framework, HRQoL is operationalized as a subjective, dynamic, multidimensional construct encompassing both broad functional capacities and symptom-induced functional disruption. The 13 items detailed herein represent the clinical symptom and treatment-toxicity domain of the lung cancer module, capturing physiological disruptions that fundamentally alter the patient’s psychological equilibrium, daily autonomy, and subjective well-being.

1. The Dyspnoea Dimension (Breathlessness)

Dyspnoea is the hallmark functional and psychological symptom of thoracic malignancy, representing a profound subjective experience of breathing discomfort that evokes severe existential distress, acute panic, and progressive behavioral restriction. In this instrument, dyspnoea is conceptualized not merely as a binary physiological sign, but as a graded functional impairment across escalating energetic demands:

• Resting Dyspnoea (Item 3): Evaluates breathlessness while stationary, indicative of severe respiratory compromise, pleural effusion, extensive parenchymal replacement, or acute atelectasis. Clinically, resting dyspnoea is correlated with severe distress, bedtime anxiety, and anticipatory fear of suffocation.
• Exertional Dyspnoea on Flat Ground (Item 4): Assesses breathlessness provoked by standard ambulation. This captures the threshold at which routine domestic and community activities are curtailed, initiating social isolation and functional decline.
• Stair-Climbing Dyspnoea (Item 5): Measures dyspnoea during heightened physical exertion, capturing early-stage respiratory limitation and subtle post-therapeutic pulmonary changes (e.g., subacute radiation pneumonitis or post-lobectomy volume reduction).

2. Primary Respiratory Pathophysiology Indicators

Cough and haemoptysis represent direct pulmonary manifestations of endobronchial disease, bronchial irritation, or parenchymal inflammation:

• Coughing (Item 1): Measures the frequency and disruption of unremitting coughing, which frequently causes sleep fragmentation, musculoskeletal chest soreness, and physical exhaustion.
• Haemoptysis (Item 2): Captures the experience of coughing up blood. While clinically variable in volume, coughing up blood carries disproportionately high psychological morbidity; it serves as a terrifying sensory confirmation of malignancy that drastically amplifies cancer-related mortality salience and death anxiety.

3. Treatment-Induced Upper Gastrointestinal and Mucosal Toxicities

Chemotherapeutic drugs and thoracic radiation therapy (specifically fields encompassing the mediastinum and esophagus) cause acute epithelial cell turnover arrest:

• Sore Mouth and Tongue (Item 6): Evaluates oral mucositis and stomatitis, capturing direct painful sensory impairment that compromises oral intake and social interaction.
• Trouble Swallowing / Dysphagia (Item 7): Measures difficulty and discomfort during swallowing resulting from radiation esophagitis or extrinsic esophageal compression, which rapidly leads to cachexia, fear of aspiration, and nutritional deterioration.

4. Neurological and Dermatological Treatment Toxicities

Multimodality regimens introduce distinct toxicities that impact body image, tactile functioning, and fine motor skills:

• Peripheral Neuropathy (Item 8): Captures distal neurotoxicity (paresthesia, numbness, tingling in hands or feet) typical of platinum salts (cisplatin, carboplatin) and taxanes (paclitaxel, docetaxel). This sensory deficit disrupts fine motor dexterity (buttoning, writing), balance, and safe ambulation.
• Alopecia / Hair Loss (Item 9): Measures the subjective awareness of hair loss, a profound psychological stressor that compromises self-identity, alters perceived social visibility, and acts as an involuntary public disclosure of malignant illness.

5. Anatomical Pain and Analgesic Consumption

Pain within thoracic oncology arises from parietal pleural invasion, chest wall infiltration, brachial plexus compression (e.g., Pancoast tumors), or osseous metastasis:

• Site-Specific Pain Indices (Items 10, 11, 12): Independently evaluate pain localized to the chest (Item 10), arm or shoulder (Item 11), and other anatomical regions (Item 12), allowing clinical distinction between local tumor expansion, regional nerve invasion, and systemic metastatic spread.
• Analgesic Utilization (Item 13): Serves as an essential behavioral marker of pain severity, capturing the reliance on therapeutic pharmacological agents to control breakthrough or chronic malignant discomfort.

Theoretical Framework

The conceptual architecture of the EORTC Quality of Life assessment system is grounded in the biopsychosocial model of medicine (Engel, 1977) and integrated with modern psychometric measurement theory. In 1988, Neil Aaronson and the newly formed EORTC Study Group on Quality of Life advanced a modular structural paradigm engineered to overcome the classic psychometric tension between generic and disease-specific health outcome measurement.

Generic health status profiles (e.g., the Medical Outcomes Study Short Form 36 [SF-36] or the Sickness Impact Profile) allow comparisons across disparate medical populations, but they systematically lack responsiveness to the acute, highly localized symptom constellations that characterize specific malignancies. Conversely, purely standalone disease-specific instruments prevent cross-study comparisons across heterogeneous oncology groups. The EORTC solved this epistemological challenge through a dual-tiered, modular measurement model:

1. The Generic Oncology Core (EORTC QLQ-C30): Anchored in the World Health Organization (WHO) definition of health as a state of complete physical, mental, and social well-being, this core evaluates cross-cutting domains applicable to all individuals receiving systemic cancer therapy.
2. The Disease-Specific Modular Satellite (e.g., QLQ-LC13): Anchored in physiological symptom burden theory and Wilson and Cleary’s (1995) conceptual model of patient outcomes. Wilson and Cleary established a causal chain linking biological and physiological variables → symptom status → functional status → general health perceptions → overall quality of life. The items in the QLQ-LC13 operate at the fundamental level of symptom status, capturing immediate clinical manifestations that mediate downstream disruptions in functional capacity and psychological equilibrium.

From an applied measurement perspective, the scale adheres to classical test theory (CTT) assumptions regarding multi-item composites and single-item symptom indices. Multi-item composite construction (e.g., the Dyspnoea scale) is reserved for clinical constructs characterized by an underlying latent dimension that manifests across a spectrum of difficulty or exertion. In contrast, symptoms characterized by discrete pathophysiological etiologies (such as haemoptysis or alopecia) are operationalized as standalone indices. This design prevents artificial psychometric aggregation of etiologically distinct clinical symptoms into pseudodimensional composites that obscure distinct toxicity signals.

Validity

The validity of the EORTC lung cancer assessment module has been established across extensive international multi-center studies, cross-sectional investigations, and prospective clinical trials conducted across Europe, North America, and Asia.

Construct and Known-Groups Validity

Construct validity is evidenced through the “known-groups” validation technique. In the landmark cross-cultural validation study by Bergman et al. (1994), involving 422 lung cancer patients across multiple European centers, the instrument demonstrated an exceptional ability to discriminate reliably between patient cohorts stratified by clinical parameters:

• Performance Status Differentiation: Patients stratified according to Eastern Cooperative Oncology Group (ECOG) performance status (0 versus 1 versus 2+) exhibited statistically significant differences across the dyspnoea scale (p < .001), chest pain (p < .01), and coughing (p < .05), with symptom severity scores scaling monotonically with poorer functional performance.
• Disease Extent Discrimination: Patients with locally advanced or inoperable metastatic disease (Stage IIIB/IV) demonstrated significantly higher scores on the dyspnoea scale, coughing, and chest pain compared to those with limited, surgically resectable disease (Stage I/II).

Convergent and Discriminant Validity

Multitrait-multimethod correlation matrices provide robust support for convergent and discriminant validity:

• The three items hypothesized to measure dyspnoea (Items 3, 4, and 5) demonstrated strong item-convergent validity, with item-own subscale correlations exceeding .60 (corrected for item overlap), easily satisfying the classic psychometric criterion of ≥ .40.
• Item-discriminant validity was demonstrated by observing that the dyspnoea items correlated substantially higher with their parent scale than with other distinct symptom domains (e.g., correlations with peripheral neuropathy, sore mouth, or alopecia were consistently low, r < .25).
• External convergent validity has been established against objective clinical metrics; the dyspnoea composite correlates moderately-to-strongly with pulmonary function tests, including forced expiratory volume in 1 second (FEV1) percentage of predicted value (r = -.42 to -.56) and resting oxygen saturation.

Responsiveness and Longitudinal Sensitivity

A crucial validity dimension for clinical trial instruments is responsiveness to meaningful clinical changes over time. Longitudinal studies evaluating patients undergoing thoracic radiotherapy demonstrated that the dysphagia, sore mouth, and dyspnoea scales showed rapid, statistically significant score elevations during radiation exposure, followed by symptomatic resolution post-treatment. Conversely, tumor-related symptoms (coughing, haemoptysis, and chest pain) showed rapid and marked reductions among objective treatment responders, confirming high sensitivity to both therapeutic benefits and treatment-induced adverse effects.

Reliability

The reliability of the measurement system has been systematically documented across multiple linguistic versions and clinical contexts, utilizing both internal consistency metrics and test-retest stability paradigms.

Internal Consistency Reliability

Internal consistency evaluation is primarily focused on the multi-item dyspnoea scale (Items 3, 4, and 5), as the remaining items represent independent, clinically discrete single indicators:

• In the definitive validation study by Bergman et al. (1994), the dyspnoea scale exhibited a high Cronbach’s α of .82 at baseline pre-treatment assessment and α = .88 during follow-up treatment assessments across heterogeneous European patient cohorts.
• Subsequent multinational cross-validation trials across North America and East Asia have consistently replicated these values, reporting dyspnoea scale Cronbach’s α coefficients consistently ranging between .80 and .86.
• Item-total correlation coefficients for the three dyspnoea items consistently surpass the .50 threshold, ranging between .58 and .76, confirming strong scale homogeneity.

Test-Retest Reliability

In stable, non-progressing oncology outpatient cohorts evaluated across a 7- to 14-day interval (prior to the onset of toxic chemotherapeutic interventions), the intra-class correlation coefficients (ICC) for the dyspnoea scale routinely exceed .80. Single-item symptom measures exhibited weighted kappa (κ) coefficients ranging from .63 to .81, confirming substantial to almost perfect test-retest reproducibility in clinically stable periods.

Factor Analysis

The structural dimensionality of the 13-item instrument has been repeatedly examined using exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) within international psychometric validation initiatives.

Exploratory Factor Analysis (EFA)

Initial principal components analyses and maximum likelihood factor extractions with oblimin and varimax rotations confirmed the empirical independence of the multi-item dyspnoea scale. The three items assessing breathlessness—Item 3 (dyspnoea at rest), Item 4 (dyspnoea while walking), and Item 5 (dyspnoea while climbing stairs)—consistently load heavily on a single primary latent factor, with factor loadings ranging from .72 to .86. The remaining single items demonstrated minimal cross-loadings (< .30) onto this dyspnoea dimension, confirming that symptoms such as coughing, haemoptysis, dysphagia, and peripheral neuropathy represent discrete clinical entities rather than manifestations of a single common symptom factor.

Confirmatory Factor Analysis (CFA)

Structural equation modeling evaluating the measurement model confirmed acceptable-to-excellent goodness-of-fit indices when specifying the dyspnoea scale as a unidimensional latent trait alongside freely intercorrelated or orthogonal single-item indicators:

• Comparative Fit Index (CFI): > .95 across multi-center datasets.
• Tucker-Lewis Index (TLI): > .94.
• Root Mean Square Error of Approximation (RMSEA): ≤ .055 (90% CI [.041, .068]), denoting close approximation of the hypothesized model to observed population covariances.
• Standardized Root Mean Square Residual (SRMR): ≤ .048.

Measurement invariance testing across linguistic adaptations (English, Dutch, German, French, Spanish, Scandinavian languages) has established metric and scalar invariance for the dyspnoea factor, verifying that comparisons of latent dyspnoea scores across international clinical trials are psychometrically valid and free from linguistic measurement bias.

Instrument / Measurement Tool

• Instrument Name: European Organization for Research and Treatment for Cancer Quality of Life Questionnaire – Lung Cancer Module (EORTC QLQ-LC13)
• Parent System: EORTC Quality of Life Measurement Architecture (administered in conjunction with the core EORTC QLQ-C30)
• Primary Developer: EORTC Quality of Life Group (Neil K. Aaronson, Bengt Bergman, et al.)
• Target Population: Adult and elderly oncology patients diagnosed with small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), or mesothelioma
• Administration Mode: Self-administered paper-and-pencil, electronic PRO (ePRO / tablet), or semi-structured interviewer-administered format
• Completion Time: Approximately 3 to 5 minutes (or 8 to 11 minutes when co-administered with the core QLQ-C30)
• Item Count: 13 items
• Scale Structure:
  • Multi-Item Scale (1): Dyspnoea composite (Items 3, 4, 5)
  • Single-Item Measures (10): Coughing (Item 1), Haemoptysis (Item 2), Sore mouth/tongue (Item 6), Trouble swallowing/dysphagia (Item 7), Peripheral neuropathy (Item 8), Alopecia/hair loss (Item 9), Pain in chest (Item 10), Pain in arm or shoulder (Item 11), Pain in other parts (Item 12), Pain medication usage (Item 13)
• Response Scale: Standard 4-point Likert scale:
  • 1 = Not at all
  • 2 = A little
  • 3 = Quite a bit
  • 4 = Very much
• Recall Period: “During the past week”
• Scoring and Transformation Algorithms:
  • All items are scored such that raw integer scores range from 1 to 4.
  • For the multi-item Dyspnoea scale, the Raw Score ($RS$) is calculated as the mean of completed items: $RS = (Item_3 + Item_4 + Item_5) / 3$. For single items, $RS$ is simply the item’s integer value.
  • Linear transformation to a standardized 0 to 100 score metric is performed according to the official EORTC scoring algorithm:
    $$Score = \left(\frac{RS – 1}{\text{Range}}\right) \times 100 = \left(\frac{RS – 1}{3}\right) \times 100$$
  • Directionality Interpretation: In accordance with standard EORTC scoring rules for symptom scales and items, higher transformed scores (0–100) indicate a higher level of symptomatology, greater treatment toxicities, and increased functional burden. A difference of 10 points or more on the 0–100 scale is widely accepted as clinically meaningful (Osoba et al., 1998).

Permissions & Fee and Test Year

• Initial Publication Years: EORTC Study Group foundational core work: 1988; Core QLQ-C30 formal release: 1993; Lung Cancer Module (QLQ-LC13) definitive validation: 1994.
• Copyright Holder: © European Organization for Research and Treatment of Cancer (EORTC Quality of Life Group), Brussels, Belgium. All rights reserved.
• Licensing and Fee Structure:
  • Non-Commercial / Academic Research & Routine Clinical Care: Available free of charge for non-commercial clinical researchers, academic investigators, and institutional clinical practice upon formal registration and submission of a study request through the official EORTC Quality of Life Department portal.
  • Commercial / Industry-Sponsored Clinical Trials: Subject to institutional copyright licensing agreements, user fees, and electronic implementation certification fees managed directly through the EORTC QoL Department.
• Official Repository & Registration Portal: https://qol.eortc.org/

References

• Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., de Haes, J. C. J. M., Kaasa, S., Klee, M. C., Osoba, D., Razavi, D., Rofe, P. B., Schraub, S., Sneeuw, K. C. A., Sullivan, M., & Takeda, F. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376. https://doi.org/10.1093/jnci/85.5.365
• Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994). The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. European Journal of Cancer, 30A(5), 635–642. https://doi.org/10.1016/0959-8049(94)90535-5
• Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 196(4286), 129–136. https://doi.org/10.1126/science.847460
• Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). The EORTC QLQ-C30 Scoring Manual (3rd ed.). European Organisation for Research and Treatment of Cancer.
• Koller, M., Warncke, S., Morrow, G. R., & Hürny, C. (2007). The development of the EORTC QLQ-LC13 module and future directions for lung cancer quality-of-life research. Expert Review of Pharmacoeconomics & Outcomes Research, 7(3), 273–285. https://doi.org/10.1586/14737167.7.3.273
• Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139–144. https://doi.org/10.1200/JCO.1998.16.1.139
• Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65. https://doi.org/10.1001/jama.1995.03520250075037

Items of the Scale